Over two-thirds of breast cancers overexpress estrogen receptor (ER), which contributes to breast cancer tumorigenesis and progression.1 Targeted inhibition of ER using selective modulators is considered the optimal treatment for breast cancer patients with ER-positive tumors. Here, ESR1 is linked to breast carcinoma.